Keith W Pratz, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director, Leukemia Programs, University of Pennsylvania/Abramson Cancer Center
Section Chief Leukemia, University of Pennyslvania
Department: Medicine
Contact information
3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia, PA 19104
South Pavilion Room 12-155
Philadelphia, PA 19104
Education:
BS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Permanent linkBS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Description of Clinical Expertise
Hematologic Malignancies, Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, MDS, AML, ALL, CML, bone Marrow TransplantDescription of Research Expertise
Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, MDS, AML, ALL, CMLSelected Publications
Shira Dinner, Zhuoxin Sun, Elisabeth Paietta, Ryan Mattison, Kathryn Roberts, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Yaqi Zhao,Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith Pratz, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel DeAngelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy Bhave, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Charles Mullighan, Martin Tallman, Selina Luger, Mark Litzow: Addition of Blinatumomab to Consolidation Therapy For Younger Adults (BCR:ABL1-NEGATIVE B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)) on The ECOG-ACRIN E1910 Phase III Trial. HemaSphere - European Hematology Association Annual meeting 9(1): 26, June 2025.Harry Erba, Eunice Wang, Amir Fathi, Gail Roboz, Yazan Madanat, Stephen Strickland, Suresh Balasubramanian, James Mangan, Keith Pratz, Anjali Advani, Ivana Gojo, Jessica Altman, Marcello Rotta, Kiran Naqvi, Jorge Cortes, Mark Juckett, Leonard C. Alsfeld, James S. Blachly, Marina Kremyanskaya, Neil Palmisiano, Kalyan Nadiminti, GarySchiller, Tara L. Lin, Mohamad Khawandanah, Michael Schuster, Talha Badar, Julie Ahsan Mackey, Tianle Chen, Marcie Riches, Daniel Corum, Mollie Leoni, Amer M. Zeidan: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) In Newly Diagnosed NPM1-M or KMT2A-R Acute Myeloid Leukemia (AML): Updated Phase 1A/B Results From KOMET-007. HemaSphere - European Hematology Association Annual Meeting 9(1): 88, June 2025.
Pratz KW: Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1. Br J Haematol 206(4): 1250-1252, Apr 2025.
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. : Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Apr 2025.
Pratz KW, Erba HP : Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents. Am J Hematol 100(2): 16-22, Mar 2025.
Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M: Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood Cancer J 15(1), Mar 2025.
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9(3): 533-544, Feb 2025.
Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi: Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy Feb 2025.
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C: The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 100(1): 185-188, Jan 2025.
Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang, Harry Erba, Jessica Kaplan Altman, Suresh Kumar Balasubramanian, Gail J. Roboz, Gary J. Schiller, Christine M. McMahon, Neil D. Palmisiano, Mark B Juckett, Yazan F. Madanat, Marcello Rotta, Keith W. Pratz, George Yaghmour, Kalyan Nadiminti, Helen Wei, Marcie Riches, Daniel Corum, Mollie Leoni, Stephen Dale, Amer M. Zeidan: Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007. Blood Dec 2024.